Background
Within the last two decades, SARS and MERS coronaviruses emerged as global health concerns causing severe acute respiratory syndromes. In December 2019, a novel coronavirus (SARS-CoV-2) was identified in Wuhan, Hubei province in China. The SARS-CoV genome encodes several proteases including chymotrypsin-like protease (CLPro; 3CLp); this key enzyme along with PLPro and PLP2 (PLPro2) drives the early stage of infection by processing a large viral polypeptide into functional enzymes. This process is essential for the replication of the virus. SARS-CoV 3CLPro shares a 96% identity in protein sequence with 3CLPro from SARS-CoV-2. The 3CLPro represents an antiviral drug target for counteracting SARS-CoV and MERS-CoV infections.Info
| Species | SARS-CoV |
| Source | E. coli |
| Tag | None |
| Molecular Weight | 34 kDa |
| Quantity | 100µg |
| Concentration | Variable |
| Formulation | |
| Storage | -80o C. Avoid repeated freeze/thaw cycles. |